精神药物市场规模、份额、成长分析（按药物类型、应用、药物类别、疾病、分销管道和地区）－2025-2032 年产业预测

预计 2023 年全球精神药物市场价值将达到 238 亿美元，从 2024 年的 248 亿美元成长到 2032 年的 344.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.2%。

全球精神药物市场正经历显着成长，这得益于人们对心理健康问题的认识不断提高以及焦虑症和忧郁症盛行率的上升。医疗保健可近性的改善以及药物研发技术的进步，都促进了这一增长。此外，精神病治疗的接受度不断提高以及政府旨在加强心理健康计画的扶持政策，也进一步推动了市场需求。新兴经济体的发展和可支配收入水准的提高也推动了这一趋势，从而推动了全球精神药物的使用增加。因此，这些因素共同凸显了不断变化的市场格局和市场潜力，凸显了在成熟市场和新兴市场中解决心理健康问题的重要性。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

精神药物市场规模（按药物类型和复合年增长率）（2025-2032）

• 市场概况
• Aripiprazole
• 布昔吡唑
• Olanzapine
• Peri-Peri酸哌利酮
• 氯氮平
• Quetiapine
• 氯丙嗪
• Risperidone
• 帕罗西汀
• 硫利达嗪
• 氟伏沙明
• 其他药物类型

精神药物市场规模：依应用和复合年增长率（2025-2032）

• 市场概况
• 抗精神病药物
• 抗焦虑
• 情绪稳定剂
• 抗忧郁症
• 兴奋剂
• 催眠药
• 抗癫痫药物
• 其他用途

精神药物市场规模：依治疗层级及复合年增长率（2025-2032）

• 市场概况
• 第一代
• 第二代
• 第三代

精神药物市场规模：依疾病及复合年增长率（2025-2032）

• 市场概况
• 思觉失调症
• 躁郁症
• 单相忧郁症
• 失智
• 其他疾病

精神药物市场规模：依分销管道及复合年增长率（2025-2032）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

精神药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比比较（2022-2024 年）

主要企业简介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca Plc（UK）
• Otsuka Holdings Co., Ltd.（Japan）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• GlaxoSmithKline（GSK）（UK）
• Bristol-Myers Squibb（BMS）（USA）
• H. Lundbeck A/S（Denmark）
• Janssen Pharmaceuticals（J&J Subsidiary）（USA）
• Viatris Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck & Co., Inc.（USA）
• Roche Holding AG（Switzerland）
• Jazz Pharmaceuticals plc（Ireland）
• Neurocrine Biosciences, Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Biogen Inc.（USA）

结论和建议

Global Psychotropic Drugs Market size was valued at USD 23.8 billion in 2023 and is poised to grow from USD 24.8 billion in 2024 to USD 34.47 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global psychotropic drugs market is experiencing significant growth, propelled by a heightened awareness of mental health issues and rising incidences of anxiety and depression. Enhanced healthcare accessibility is contributing to this expansion, alongside advancements in drug development technologies. Furthermore, the increasing acceptance of psychiatric treatments and supportive government initiatives aimed at bolstering mental health programs are further driving market demand. The trend is also supported by emerging economies and a rise in discretionary income levels, facilitating greater utilization of psychotropic medications globally. As a result, these factors collectively underscore the evolving landscape and potential of the psychotropic drugs market, highlighting the importance of addressing mental health in both established and developing markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychotropic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychotropic Drugs Market Segments Analysis

Global Psychotropic Drugs Market is segmented by Drug Type, Application, Therapeutic Class, Disease, Distribution Channel and region. Based on Drug Type, the market is segmented into Aripiprazole, Brexipiprazole, Olanzapine, Peliperidone Palmitate, Clozapine, Quetiapine, Chlorpromazine, Risperidone, Paroxetine, Thioridazine, Fluvoxamine and Other Drug Types. Based on Application, the market is segmented into Anti-Psychotics, Anti-Anxiety, Mood Stabilizers, Antidepressants, Stimulants, Hypnotics, Antiepileptic Drugs and Other Applications. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is experiencing growth driven by increased awareness surrounding mental health, bolstered by public information campaigns and support from celebrity advocates that have normalized mental health treatment. This heightened awareness has led to more frequent diagnoses of mental illnesses. Furthermore, supportive government initiatives and strategic workplace wellness programs have enhanced the accessibility and prescription rates of various psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, particularly among urban populations facing high levels of stress. The combination of these factors is fostering a greater acceptance and utilization of mental health treatments on a global scale.

Restraints in the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market faces significant constraints due to the rigorous safety and efficacy evaluations conducted by regulatory authorities, which prolong the time to market for new products. The complexity of conducting clinical trials for mental health disorders, particularly given the subjective nature of diagnoses, contributes to elevated development costs. Furthermore, the necessity for stringent post-marketing surveillance, such as monitoring for potential suicide risks associated with antidepressants, compounds these financial challenges, particularly for smaller pharmaceutical companies that may lack the resources to manage such burdens. These factors collectively hinder innovation and timely market entry in this sector.

Market Trends of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is increasingly shifting towards precision medicine, emphasizing personalized treatment options that utilize genetic testing and biomarker-driven approaches. Advancements in pharmacogenomics and the identification of biomarkers, such as BDNF levels and CYP450 enzyme profiles, are enhancing the ability to tailor psychotropic medications to individual patient needs, thereby reducing the trial-and-error approach traditionally associated with prescribing. This trend is further propelled by innovative companies developing psychedelic-based therapies, which are garnering significant venture capital investments and fostering partnerships within the healthcare ecosystem, ultimately driving growth and transformation in the psychotropic drugs sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Psychotropic Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Aripiprazole
• Brexipiprazole
• Olanzapine
• Peliperidone Palmitate
• Clozapine
• Quetiapine
• Chlorpromazine
• Risperidone
• Paroxetine
• Thioridazine
• Fluvoxamine
• Other Drug Types

Global Psychotropic Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Anti-Psychotics
• Anti-Anxiety
• Mood Stabilizers
• Antidepressants
• Stimulants
• Hypnotics
• Antiepileptic Drugs
• Other Applications

Global Psychotropic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Psychotropic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Psychotropic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Psychotropic Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (J&J Subsidiary) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations